enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Dexlansoprazole - Wikipedia

    en.wikipedia.org/wiki/Dexlansoprazole

    Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). [2] It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. [8]

  3. Discovery and development of proton pump inhibitors - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    Dexlansoprazole is an (R)-(+)-enantiomer of lansoprazole, marketed as Dexilant. After oral appliance of the racemic lansoprazole, the circulating drug is 80% dexlansoprazole. Moreover, both enantiomers have similar effects on the proton pump. [15] Consequently, the main advantage of Dexilant is not the fact that it is an enantiopure substance.

  4. Category : Drugs developed by Takeda Pharmaceutical Company

    en.wikipedia.org/wiki/Category:Drugs_developed...

    Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more

  5. Takeda's treatment becomes first oral therapy for esophageal ...

    www.aol.com/news/us-fda-approves-takedas-therapy...

    Takeda's treatment will be available in stick packs of 2 milligram doses by the end of February, the company said. The company has set wholesale acquisition cost for the therapy, given twice daily ...

  6. Takeda's seizure drug fails to meet main goal in late-stage ...

    www.aol.com/news/takedas-seizure-drug-fails-meet...

    DS affects about one in 21,000 people and LGS affects fewer than one in 1,000 people in the United States, according to Takeda. The treatments currently available in the U.S. for both the condi.

  7. TAP Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/TAP_Pharmaceuticals

    Abbott and Takeda agreed to end the partnership in 2008, with Abbott keeping the rights to leuprorelin, which had sales in 2007 of $600 million and a patent expiring in 2015 and the approximately 300 employees who worked on the product, and Takeda keeping the rights to lansoprazole, which had sales of $2.3 billion in 2007 but was facing ...

  8. Takeda Pharma gets US FDA approval for rare blood disorder ...

    www.aol.com/news/takeda-pharma-gets-fda-approval...

    Takeda's Adzynma becomes the first treatment available to patients with congenital thrombotic thrombocytopenic purpura (TTP). Congenital TTP is a life-threatening, rare genetic disorder with ...

  9. Vonoprazan - Wikipedia

    en.wikipedia.org/wiki/Vonoprazan

    Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. [2] [1] Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.